Data / Research funding / Maryland / Sanaria, Inc.
Sanaria, Inc.: 20 NIH awards ($39.5M), fiscal years 2021 to 2026
Sanaria, Inc. in Rockville, MD is funded under 20 NIH awards ($39.5M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- YLF2SS2NYGC5
- State
- Maryland
Awards
20 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,933,702 | April 8, 2021 | March 31, 2027 | SIM, B. KIM LEE | reporter.nih.gov |
| Development of Non-Human Primate Models to Assess Immunological Mechanisms and Antigenic Targets of Protective Sporozoite (SPZ) Vaccines and Establish Superior Efficacy of Next Generation SPZ vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,717,265 | April 1, 2021 | March 31, 2027 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| A Unique Automated Bioreactor for Rearing Aseptic Mosquitoes from Larvae to Adults to Support Manufacture of Sanaria PfSPZ Products | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,000,000 | July 18, 2018 | March 31, 2025 | BILLINGSLEY, PETER F. | reporter.nih.gov |
| A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,998,001 | April 21, 2020 | March 31, 2027 | SIM, B. KIM LEE | reporter.nih.gov |
| Progressing PfSPZ vaccines for malaria to licensure and commercialization | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,994,338 | April 14, 2023 | March 31, 2027 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with an attenuated, live sporozoite malaria vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,935,817 | July 1, 2016 | June 30, 2025 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Automating mosquito microdissection for a malaria PfSPZ vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,924,306 | June 20, 2017 | April 30, 2025 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,995,482 | April 21, 2016 | July 31, 2027 | CHAKRAVARTY, SUMANA | reporter.nih.gov |
| PfSPZ Vaccine for Malaria: Towards a Successful Biologics License Application and Commercialization | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,973,577 | February 15, 2004 | June 30, 2023 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,938,759 | April 21, 2016 | May 31, 2024 | CHAKRAVARTY, SUMANA | reporter.nih.gov |
| Cryopreservation of Anopheles Embryos | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,928,928 | August 1, 2010 | January 31, 2024 | BILLINGSLEY, PETER F. | reporter.nih.gov |
| In-Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,912,715 | February 15, 2010 | May 31, 2025 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| PfSPZ Vaccine for Prevention of Plasmodium falciparum malaria | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $988,772 | September 1, 2022 | June 30, 2024 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Attenuation of Liquid Formulation for PfSPZ Vaccine by X-Ray | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $600,000 | April 12, 2021 | March 31, 2024 | JAMES, ERIC ROBERT | reporter.nih.gov |
| In vitro bioreactor production of a genetically modified late liver stage-arresting replication competent Plasmodium falciparum sporozoite vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $600,000 | June 3, 2022 | May 31, 2025 | SIM, B. KIM LEE | reporter.nih.gov |
| Conditional male lethal Anopheles stephensi line for the efficient manufacture of malaria vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $599,951 | February 14, 2023 | January 31, 2025 | BILLINGSLEY, PETER F. | reporter.nih.gov |
| Modularizing manufacture of PfSPZ vaccines: ookinete production for PfSPZ manufacture in mosquitoes and in vitro | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $559,942 | September 6, 2023 | August 31, 2025 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage. | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $300,000 | April 21, 2020 | March 31, 2023 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Enhancement of gametocytogenesis in Plasmodium falciparum by genetic engineering for improved PfSPZ Vaccine Manufacture | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $299,994 | August 17, 2020 | July 31, 2023 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Development of monoclonal antibody-mediated interventions to combat malaria | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $298,596 | August 30, 2022 | August 31, 2023 | RUPPRECHT, SUSAN | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 5 | $4,951,927 | 0 | $0 |
| 2024 | 8 | $6,566,260 | 0 | $0 |
| 2023 | 10 | $7,994,713 | 0 | $0 |
| 2022 | 13 | $10,924,421 | 0 | $0 |
| 2021 | 11 | $9,062,824 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 19 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 19 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 19 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 19 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 19 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 19 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 19 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 19 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 19 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 19 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 19 awards here |
| Immune Tolerance Network (UM1 Clinical Trial Required) | RFA-AI-28-005 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 19 awards here |
| Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed) | RFA-AI-28-012 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 19 awards here |
| Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) | RFA-AI-28-024 | NIH | 93.855 | February 11, 2027 | Not listed | Same assistance listing 93.855 as 19 awards here |
| NLM Institutional Grants for Research Training in Biomedical Informatics, Data Science, and AI (T15 Independent Clinical Trial Not Allowed) | RFA-LM-28-001 | NIH | 93.855 | February 11, 2027 | $775,000 | Same assistance listing 93.855 as 19 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 19 awards here |
| NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) | PA-27-102 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 19 awards here |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 19 awards here |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) | PA-24-185 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 19 awards here |
| Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required) | PA-24-187 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 19 awards here |
Topics of its NIH awards
- Infectious Diseases
- Malaria
- Rare Diseases
- Vector-Borne Diseases
- Immunization
- Orphan Drug
- Prevention
- Vaccine Related
- Malaria Vaccine
- Biotechnology
- Emerging Infectious Diseases
- Translational Research
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.